PULMOTECT, INC. is a bio-pharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.
Our technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague).
Awards
The technology has been awarded multiple grant and equity funding awards (PI of award).
- Initial Close on Series B Round in 2018
- Series A Round completed in 2016
- Texas Emerging Technology Fund (Dr. Scott)
- NIH five year collaborative award with leading academic institutions (Dr. Hook)
- U.T.M.D. Anderson Cancer Center MRP Award (Dr. Dickey)
- Fannin Innovation Studio Partnership
- “Living Legends” fund (Dr. Dickey)
- Culpeper award (Dr. Evans)
- NCI Leukemia SPORE grant (Dr. Evans)
- Inaugural Texas Ignition Fund award
- Lehman Brothers Foundation award (Dr. Dickey)
- NHLBI R01 on mechanisms of inducible resistance
(Dr. Evans) - NHLBI/Office of the Director New Innovator Award
(Dr. Evans) - TJ Martell Foundation on mechanisms of inducible resistance (Dr. Evans)
- U.T. M. D. Anderson Cancer Center – Technology Review Committee
- Seven NIH SBIR awards (Dr. Scott)
- Cancer Prevention Research Institute of Texas (Dr. Scott)
Recognition
- SE Bio Investor Forum winner
- Rice Alliance Conference, awarded a “Most Promising Company” award
- Top three award from SBIR National Conference
- World’s Best Technology Showcase presentation
- Top 5 company award at the national NCET2 conference in Washington DC
- Graduate Client Company of the Houston Technology Center
- American Society for Cell Biology “Press Book” selection
- Featured on front page of Houston Chronicle
- Featured in BusinessWeek, Forbes, USNews, Washington Post and multiple other media sources
- Selected to exhibit and showcase technology at the 2017 Biotechnology Innovation Organization conference
- Selected to present at the 2017 Biotech Showcase conference